Sandoz is the global leader in generic and biosimilar medicines, with a growth strategy driven by its Purpose: pioneering access for patients. More than 20,000 people of 100 nationalities work together to ensure 900 million patient treatments are provided by Sandoz annually, generating substantial global healthcare savings and an even larger social impact. Its leading portfolio of approximately 1,300 products addresses diseases from the common cold to cancer. Headquartered in Basel, Switzerland, Sandoz traces its heritage back to 1886. Its history of breakthroughs includes Calcium Sandoz in 1929, the world’s first oral penicillin in 1951, and the world’s first biosimilar in 2006. In 2024, Sandoz recorded net sales of USD 10.4 billion. Read our community engagement guidelines: http://bit.ly/4ofoggc
Unlock the market timeline & signal feed
150 signals in the last 90 days.
The order this company entered each market — oldest to newest
10 active postings
54 active postings
Sign up to see the full signal feed
How Sandoz's international expansion compares to its competitors
SandozYouBars show relative size across the companies compared.
Columns5| Company | Markets | New markets | Momentum | Activity | Expansion score |
|---|---|---|---|---|---|
 SandozYou | 25 | 1 | +245% | 138 | 32 |
Launch Manager
View postingKyiv, Kyiv City, Ukraine · today
Medical Representative (Ha Noi)
View postingVietnam · yesterday
Медицинский представитель (Medical Line) - г. Ярославль
View postingYaroslavl, Yaroslavl’, Russia · Full-time · yesterday
Personal growth & learning at Sandoz
EndedAntimicrobial resistance is reducing the effectiveness of antibiotics – medicines that underpin our modern healthcare system. Without antibiotics, routine infections become harder to treat and complex procedures carry greater risk. In the United States, more than 2.8 million antimicrobial resistant infections occur each year, according to the CDC. This is not a future threat. It is already here.As an industry, we all have a role to play to ensure reliable access to high quality antibiotics, buil ...
Ended
Join us!
ActiveHenlius reports 2.7% revenue growth, 10.5% gross profit increase, and 206.8% operating cash flow growth in H1 2025. Overseas product profits surge over 200%.
Henlius reports 2.7% revenue growth, 10.5% gross profit increase, and 206.8% operating cash flow growth in H1 2025. Overseas product profits surged over 200%.
Sandoz launches generic rivaroxaban in Germany at 10, 15, and 20 mg dosages, offering a high-quality, affordable alternative to Xarelto with catalog price advantages.
Unlock verified emails & direct dials
Free · No credit card needed
Quick answers about Sandoz's business, markets, and growth signals.
Pubrio glocalizes business, people, and intent data from 50+ local sources into one global graph, giving AI and revenue teams full‑market visibility.
© 2026 Pubrio. All rights reserved.
